30523067 2020-01-01 2020-12-31 30523067 2020-01-01 2020-12-31 0 30523067 2019-01-01 2019-12-31 30523067 2020-01-01 2020-12-31 fsa:RetainedEarningsMember 30523067 2019-01-01 2019-12-31 fsa:RetainedEarningsMember 30523067 2020-12-31 30523067 2019-12-31 30523067 2020-01-01 2020-12-31 0 iso4217:DKK 2020-01-01 2020-12-31 <table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">Liquidator’s Statement</td></tr></table> <table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">The Liquidator has today considered and adopted the Annual Report of EpiTherapeutics ApS under</td></tr><tr><td colspan="1">frivillig likvidation for the financial year 1 January - 31 December 2020.</td></tr></table> <table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">The Annual Report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table> <table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">In our opinion the Financial Statements give a true and fair view of the financial position at 31 December</td></tr><tr><td colspan="1">2020 of the Company and of the results of the Company operations for the year ended 31 December 2020.</td></tr></table> <table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">In our opinion, Liquidator's Review includes a true and fair account of the matters addressed in the</td></tr><tr><td colspan="1">Review.</td></tr></table> <table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">We recommend that the Annual Report be adopted at the Annual General Meeting.</td></tr></table> Copenhagen 2021-03-29 <table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">Independent auditor's report</td></tr></table> <table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">To the liquidator of EpiTherapeutics ApS under frivillig likvidation</td></tr></table> <table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">Opinion</td></tr><tr><td colspan="1">We have audited the financial statements of EpiTherapeutics ApS under frivillig likvidation for the</td></tr><tr><td colspan="1">financial year 1 January – 31 December 2020, which comprise an income statement, balance sheet,</td></tr><tr><td colspan="1">statement of changes in equity and notes, including accounting policies. The financial statements are</td></tr><tr><td colspan="1">prepared in accordance with the Danish Financial Statements Act.</td></tr><tr><td colspan="1">In our opinion, the financial statements give a true and fair view of the financial position of the Company</td></tr><tr><td colspan="1">at 31 December 2020 and of the results of the Company's operations for the financial year 1 January –</td></tr><tr><td colspan="1">31 December 2020 in accordance with the Danish Financial Statements Act.</td></tr></table> <table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">Basis for opinion</td></tr><tr><td colspan="1">We conducted our audit in accordance with International Standards on Auditing (ISAs) and additional</td></tr><tr><td colspan="1">requirements applicable in Denmark. Our responsibilities under those standards and requirements are</td></tr><tr><td colspan="1">further described in the "Auditor's responsibilities for the audit of the financial statements" section of our</td></tr><tr><td colspan="1">report. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a</td></tr><tr><td colspan="1">basis for our opinion.</td></tr><tr><td colspan="1">Independence</td></tr><tr><td colspan="1">We are independent of the Company in accordance with the International Ethics Standards Board for</td></tr><tr><td colspan="1">Accountants' Code of Ethics for Professional Accountants (IESBA Code) and additional requirements</td></tr><tr><td colspan="1">applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these</td></tr><tr><td colspan="1">rules and requirements.</td></tr></table> <table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">Liquidator's responsibilities for the financial statements</td></tr><tr><td colspan="1">Liquidator is responsible for the preparation of financial statements that give a true and fair view in</td></tr><tr><td colspan="1">accordance with the Danish Financial Statements Act and for such internal control as Liquidator</td></tr><tr><td colspan="1">determines is necessary to enable the preparation of financial statements that are free from material</td></tr><tr><td colspan="1">misstatement, whether due to fraud or error.</td></tr><tr><td colspan="1">In preparing the financial statements, Liquidator is responsible for assessing the Company's ability to</td></tr><tr><td colspan="1">continue as a going concern, disclosing, as applicable, matters related to going concern and using the</td></tr><tr><td colspan="1">going concern basis of accounting in preparing the financial statements unless Liquidator either intends</td></tr><tr><td colspan="1">to liquidate the Company or to cease operations, or has no realistic alternative but to do so.</td></tr></table> <table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="2">Auditor's responsibilities for the audit of the financial statements</td></tr><tr><td colspan="2">Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are</td></tr><tr><td colspan="2">free from material misstatement, whether due to fraud or error, and to issue an auditor's report that</td></tr><tr><td colspan="2">includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an</td></tr><tr><td colspan="2">audit conducted in accordance with ISAs and additional requirements applicable in Denmark will always</td></tr><tr><td colspan="2">detect a material misstatement when it exists. Misstatements can arise from fraud or error and are</td></tr><tr><td colspan="2">considered material if, individually or in the aggregate, they could reasonably be expected to influence the</td></tr><tr><td colspan="2">economic decisions of users taken on the basis of the financial statements.</td></tr><tr><td colspan="2">As part of an audit conducted in accordance with ISAs and additional requirements applicable in</td></tr><tr><td colspan="2">Denmark, we exercise professional judgement and maintain professional skepticism throughout the audit.</td></tr><tr><td colspan="2">We also</td></tr><tr><td>►</td><td>Identify and assess the risks of material misstatement of the financial statements, whether due to</td></tr><tr><td /><td>fraud or error, design and perform audit procedures responsive to those risks and obtain audit</td></tr><tr><td /><td>evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting</td></tr><tr><td /><td>a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may</td></tr><tr><td /><td>involve collusion, forgery, intentional omissions, misrepresentations or the override of internal</td></tr><tr><td /><td>control.</td></tr><tr><td>►</td><td>Obtain an understanding of internal control relevant to the audit in order to design audit procedures</td></tr><tr><td /><td>that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the</td></tr><tr><td /><td>effectiveness of the Company's internal control.</td></tr><tr><td>►</td><td>Evaluate the appropriateness of accounting policies used and the reasonableness of accounting</td></tr><tr><td /><td>estimates and related disclosures made by Liquidator.</td></tr><tr><td>►</td><td>Conclude on the appropriateness of Liquidator's use of the going concern basis of accounting in</td></tr><tr><td /><td>preparing the financial statements and, based on the audit evidence obtained, whether a material</td></tr><tr><td /><td>uncertainty exists related to events or conditions that may cast significant doubt on the Company's</td></tr><tr><td /><td>ability to continue as a going concern. If we conclude that a material uncertainty exists, we are</td></tr><tr><td /><td>required to draw attention in our auditor's report to the related disclosures in the financial statements</td></tr><tr><td /><td>or, if such disclosures are inadequate, to modify our opinion. Our conclusion is based on the audit</td></tr><tr><td /><td>evidence obtained up to the date of our auditor's report. However, future events or conditions may</td></tr><tr><td /><td>cause the Company to cease to continue as a going concern.</td></tr><tr><td>►</td><td>Evaluate the overall presentation, structure and contents of the financial statements, including the</td></tr><tr><td /><td>note disclosures, and whether the financial statements represent the underlying transactions and</td></tr><tr><td /><td>events in a manner that gives a true and fair view.</td></tr><tr><td colspan="2">We communicate with those charged with governance regarding, among other matters, the planned scope</td></tr><tr><td colspan="2">and timing of the audit and significant audit findings, including any significant deficiencies in internal</td></tr><tr><td colspan="2">control that we identify during our audit.</td></tr></table> <table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">Statement on the Liquidator's review</td></tr><tr><td colspan="1">Liquidator is responsible for Liquidator's review.</td></tr><tr><td colspan="1">Our opinion on the financial statements does not cover the Liquidator's review, and we do not express any</td></tr><tr><td colspan="1">form of assurance conclusion thereon.</td></tr><tr><td colspan="1">In connection with our audit of the financial statements, our responsibility is to read the Liquidator’s</td></tr><tr><td colspan="1">review and, in doing so, consider whether the Liquidator 's review is materially inconsistent with the</td></tr><tr><td colspan="1">financial statements or our knowledge obtained during the audit, or otherwise appears to be materially</td></tr><tr><td colspan="1">misstated.</td></tr><tr><td colspan="1">Moreover, it is our responsibility to consider whether the Liquidator's review provides the information</td></tr><tr><td colspan="1">required under the Danish Financial Statements Act.</td></tr><tr><td colspan="1">Based on our procedures, we conclude that Liquidator's review is in accordance with the financial</td></tr><tr><td colspan="1">statements and has been prepared in accordance with the requirements of the Danish Financial</td></tr><tr><td colspan="1">Statements Act. We did not identify any material misstatement of the Liquidator's review.</td></tr></table> Copenhagen 2021-03-29 EpiTherapeutics ApS under frivillig likvidation Amerika Plads 37 DK-2100 Copenhagen Oe 30523067 Copenhagen Plesner Advokatpartnerselskab Amerika Plads 37 DK 2100 Copenhagen Nykredit Kalvebod Brygge 1-3 1780 København V 2021-03-29 Christian Ellegaard Gejel <table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">Liquidator’s Review</td></tr></table> <table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">Main activity</td></tr><tr><td colspan="1">At the extraordinary general meeting on 10 October 2016, it was decided to dissolve the Company under</td></tr><tr><td colspan="1">the rules of solvent liquidation of the Danish Companies Act. The company remains under liquidation in</td></tr><tr><td colspan="1">2020 and there has been limited activity during the current year.</td></tr></table> <table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">Development in the year</td></tr><tr><td colspan="1">The income statement of the Company for 2020 shows a loss of DKK 3,028,693 the majority of which</td></tr><tr><td colspan="1">arises due to the write off of a deferred tax asset, and exchange rate variance and at 31 December 2020 the</td></tr><tr><td colspan="1">balance sheet of the Company shows equity of DKK 30,279,232.</td></tr></table> <table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">Uncertainty relating to recognition and measurement</td></tr><tr><td colspan="1">Recognition and measurement in the Annual Report have not been subject to any uncertainty. Covid 19</td></tr><tr><td colspan="1">has had no impact on the Company.</td></tr></table> <table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">Unusual events</td></tr><tr><td colspan="1">The financial position at 31 December 2020 of the Company, and the results of the activities of the</td></tr><tr><td colspan="1">Company for the financial year for 2020 have not been affected by any unusual events.</td></tr></table> <table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">Subsequent events</td></tr><tr><td colspan="1">No events materially effecting the assessment of the annual report have occurred after the balance sheet</td></tr><tr><td colspan="1">date.</td></tr></table> 398217 -398217 0 1308457 -1706674 1322019 -3028693 <table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td width="100%" colspan="4" align="left" valign="middle" ><b>Statement of Changes in Equity</b></td></tr><tr><td colspan="4"></td></tr><tr><td width="42%" ></td><td width="19%" ></td><td width="19%" colspan="1" align="right" valign="middle" >Retained</td><td width="20%" colspan="1" align="right" valign="middle" ></td></tr><tr><td width="42%" ></td><td width="19%" colspan="1" align="right" valign="middle" >Share capital</td><td width="19%" colspan="1" align="right" valign="middle" >earnings</td><td width="20%" colspan="1" align="right" valign="middle" >Total</td></tr><tr><td width="42%" ></td><td width="19%" colspan="1" align="right" valign="middle" >DKK</td><td width="19%" colspan="1" align="right" valign="middle" >DKK</td><td width="20%" colspan="1" align="right" valign="middle" >DKK</td></tr><tr><td colspan="4"></td></tr><tr><td width="42%" colspan="1" align="left" valign="middle" >Equity at 1 January</td><td width="19%" align="right" valign="middle" >4.545.875</td><td width="19%" align="right" valign="middle" >28.762.050</td><td width="20%" align="right" valign="middle" >33.307.925</td></tr><tr><td width="42%" colspan="1" align="left" valign="middle" >Net loss for the year</td><td width="19%" align="right" valign="middle" >0</td><td width="19%" align="right" valign="middle" >-3.028.693</td><td width="20%" align="right" valign="middle" >-3.028.693</td></tr><tr><td width="42%" colspan="1" align="left" valign="middle" ><b>Equity at 31 December</b></td><td width="19%" align="right" valign="middle" ><b>4.545.875</b></td><td width="19%" align="right" valign="middle" ><b>25.733.357</b></td><td width="20%" align="right" valign="middle" ><b>30.279.232</b></td></tr></table> <table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td width="100%" colspan="1" align="left" valign="middle" ><b>Notes</b></td></tr><tr><td colspan="1"></td></tr><tr><td width="100%" colspan="1" align="left" valign="middle" ><b>Unusual items</b></td></tr><tr><td colspan="1"></td></tr><tr><td width="100%" colspan="1" align="left" valign="middle" >The Covid-19 outbreak has not affected the Company.</td></tr><tr><td colspan="1"></td></tr></table> <table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td width="74%" colspan="4" align="left" valign="middle" ><b>Tax on profit for the year</b></td><td width="11%" align="right" valign="middle" ><b>2020</b></td><td width="15%" align="right" valign="middle" ><b>2019</b></td></tr><tr><td width="41%" ></td><td width="11%" ></td><td width="11%" ></td><td width="11%" ></td><td width="11%" colspan="1" align="right" valign="middle" ><b>DKK</b></td><td width="15%" colspan="1" align="right" valign="middle" ><b>DKK</b></td></tr><tr><td width="74%" colspan="4" align="left" valign="middle" >Current tax for the year, joint taxation contribution</td><td width="11%" align="right" valign="middle" >-1.247.722</td><td width="15%" align="right" valign="middle" >-1.215.403</td></tr><tr><td width="74%" colspan="4" align="left" valign="middle" >Deferred tax for the year</td><td width="11%" align="right" valign="middle" >2.430.806</td><td width="15%" align="right" valign="middle" >765.092</td></tr><tr><td width="74%" colspan="4" align="left" valign="middle" >Adjustment of tax concerning previous years</td><td width="11%" align="right" valign="middle" >138.935</td><td width="15%" align="right" valign="middle" >-42.678</td></tr><tr><td width="41%" ></td><td width="11%" ></td><td width="11%" ></td><td width="11%" ></td><td width="11%" align="right" valign="middle" ><b>1.322.019</b></td><td width="15%" align="right" valign="middle" ><b>-492.989</b></td></tr><tr><td colspan="6"></td></tr></table> <table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td width="100%" colspan="6" align="left" valign="middle" ><b>Equity</b></td></tr><tr><td colspan="6"></td></tr><tr><td width="100%" colspan="6" align="left" valign="middle" >The share capital is broken down as follow</td></tr><tr><td colspan="6"></td></tr><tr><td width="41%" ></td><td width="11%" ></td><td width="11%" ></td><td width="11%" ></td><td width="11%" colspan="1" align="right" valign="middle" >Number</td><td width="15%" colspan="1" align="right" valign="middle" >Nominal value</td></tr><tr><td width="41%" ></td><td width="11%" ></td><td width="11%" ></td><td width="11%" ></td><td width="11%" ></td><td width="15%" colspan="1" align="right" valign="middle" >DKK</td></tr><tr><td colspan="6"></td></tr><tr><td width="74%" colspan="4" align="left" valign="middle" >A-shares</td><td width="11%" align="right" valign="middle" >533.951</td><td width="15%" align="right" valign="middle" >533.951</td></tr><tr><td width="74%" colspan="4" align="left" valign="middle" >B-shares</td><td width="11%" align="right" valign="middle" >977.242</td><td width="15%" align="right" valign="middle" >977.242</td></tr><tr><td width="74%" colspan="4" align="left" valign="middle" >C-shares</td><td width="11%" align="right" valign="middle" >3.034.682</td><td width="15%" align="right" valign="middle" >3.034.682</td></tr><tr><td width="41%" ></td><td width="11%" ></td><td width="11%" ></td><td width="11%" ></td><td width="11%" ></td><td width="15%" align="right" valign="middle" ><b>4.545.875</b></td></tr><tr><td colspan="6"></td></tr><tr><td width="100%" colspan="6" align="left" valign="middle" >The share capital has developed as follows</td></tr><tr><td colspan="6"></td></tr><tr><td width="41%" ></td><td width="11%" align="right" valign="middle" ><b>2020</b></td><td width="11%" align="right" valign="middle" ><b>2019</b></td><td width="11%" align="right" valign="middle" ><b>2018</b></td><td width="11%" align="right" valign="middle" ><b>2017</b></td><td width="15%" align="right" valign="middle" ><b>2016</b></td></tr><tr><td width="41%" ></td><td width="11%" colspan="1" align="right" valign="middle" ><b>DKK</b></td><td width="11%" colspan="1" align="right" valign="middle" ><b>DKK</b></td><td width="11%" colspan="1" align="right" valign="middle" ><b>DKK</b></td><td width="11%" colspan="1" align="right" valign="middle" ><b>DKK</b></td><td width="15%" colspan="1" align="right" valign="middle" ><b>DKK</b></td></tr><tr><td width="41%" colspan="1" align="left" valign="middle" >Share capital at 1 January</td><td width="11%" align="right" valign="middle" >4.545.875</td><td width="11%" align="right" valign="middle" >4.545.875</td><td width="11%" align="right" valign="middle" >4.545.875</td><td width="11%" align="right" valign="middle" >4.545.875</td><td width="15%" align="right" valign="middle" >4.545.875</td></tr><tr><td width="41%" colspan="1" align="left" valign="middle" >Capital increase</td><td width="11%" align="right" valign="middle" >0</td><td width="11%" align="right" valign="middle" >0</td><td width="11%" align="right" valign="middle" >0</td><td width="11%" align="right" valign="middle" >0</td><td width="15%" align="right" valign="middle" >0</td></tr><tr><td width="100%" colspan="6" align="left" valign="middle" ><b>Share capital at 31</b></td></tr><tr><td width="41%" colspan="1" align="left" valign="middle" ><b>December</b></td><td width="11%" align="right" valign="middle" ><b>4.545.875</b></td><td width="11%" align="right" valign="middle" ><b>4.545.875</b></td><td width="11%" align="right" valign="middle" ><b>4.545.875</b></td><td width="11%" align="right" valign="middle" ><b>4.545.875</b></td><td width="15%" align="right" valign="middle" ><b>4.545.875</b></td></tr><tr><td colspan="6"></td></tr><tr><td width="41%" ></td><td width="11%" ></td><td width="11%" ></td><td width="11%" ></td><td width="11%" ></td><td width="15%" align="right" valign="middle" >9</td></tr></table> <table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1"></td></tr><tr><td width="100%" colspan="1" align="left" valign="middle" ><b>Contingent assets, liabilities and other financial obligations</b></td></tr><tr><td colspan="1"></td></tr><tr><td width="100%" colspan="1" align="left" valign="middle" ><b>Contingent liabilities</b></td></tr><tr><td colspan="1"></td></tr><tr><td width="100%" colspan="1" align="left" valign="middle" >The Danish group of Gilead companies ("Danish Group"), which is effective from 7 May 2015, are jointly and</td></tr><tr><td width="100%" colspan="1" align="left" valign="middle" >severally liable for tax on the jointly taxed income of the Danish Group and for any Danish taxes payable by the</td></tr><tr><td width="100%" colspan="1" align="left" valign="middle" >Danish Group at source such as dividend tax, tax on royalty payments and withholding tax. The total corporation</td></tr><tr><td width="100%" colspan="1" align="left" valign="middle" >tax payable is disclosed in the 2020 Annual Report of Gilead Sciences Denmark ApS, which is the management</td></tr><tr><td width="100%" colspan="1" align="left" valign="middle" >company of the joint taxation</td></tr><tr><td colspan="1"></td></tr></table> <table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td width="100%" colspan="2" align="left" valign="middle" ><b>Related parties and ownership</b></td></tr><tr><td colspan="2"></td></tr><tr><td width="78%" ></td><td width="22%" colspan="1" align="left" valign="middle" ><b>Basis</b></td></tr><tr><td colspan="2"></td></tr><tr><td width="100%" colspan="2" align="left" valign="middle" ><b>Controlling interest</b></td></tr><tr><td colspan="2"></td></tr><tr><td width="78%" colspan="1" align="left" valign="middle" >Gilead Sciences Inc.</td><td width="22%" colspan="1" align="left" valign="middle" >Parent and Ultimate parent company</td></tr><tr><td colspan="2"></td></tr><tr><td width="100%" colspan="2" align="left" valign="middle" ><b>Ownership</b></td></tr><tr><td colspan="2"></td></tr><tr><td width="100%" colspan="2" align="left" valign="middle" >The following shareholder is recorded in the Company's register of shareholders as holding at least 5% of the</td></tr><tr><td width="100%" colspan="2" align="left" valign="middle" >votes or at least 5% of the share capital</td></tr><tr><td colspan="2"></td></tr><tr><td width="100%" colspan="2" align="left" valign="middle" >Gilead Sciences Inc.</td></tr><tr><td colspan="2"></td></tr><tr><td width="100%" colspan="2" align="left" valign="middle" ><b>Consolidated Financial Statements</b></td></tr><tr><td colspan="2"></td></tr><tr><td width="100%" colspan="2" align="left" valign="middle" >The Company is included in the Group Annual Report of the ultimate parent company Gilead Sciences Inc.</td></tr><tr><td colspan="2"></td></tr></table> Regnskabsklasse B <table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td /><td>Accounting Policies</td></tr><tr><td /><td>Basis of Preparation</td></tr><tr><td /><td>Financial Statements of EpiTherapeutics ApS under frivillig likvidation for 2020 has been prepared in</td></tr><tr><td /><td>accordance with the provisions of the Danish Financial Statements Act applying to enterprises of re-</td></tr><tr><td /><td>porting class B and elective choice of certain provisions applying to reporting class C entities.</td></tr><tr><td /><td>The financial statements have been prepared in accordance with the same accounting policies as last</td></tr><tr><td /><td>year.</td></tr><tr><td /><td>Effective from the financial year 2020, the Company has implemented amending act no. 1716 of 27</td></tr><tr><td /><td>December 2018 to the Danish Financial Statements Act. The implementation of the amending act has</td></tr><tr><td /><td>not affected the Company's accounting policies on recognition and measurement of assets and</td></tr><tr><td /><td>liabilities but has solely entailed a requirement for further disclosures. The accounting policies used in</td></tr><tr><td /><td>the preparation of the financial statements are consistent with those of last year.</td></tr><tr><td /><td>Financial Statements for 2020 are presented in DKK.</td></tr></table> <table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td /><td>Recognition and measurement</td></tr><tr><td /><td>Revenues are recognised in the income statement as earned. Furthermore, value adjustments of fi-</td></tr><tr><td /><td>nancial assets and liabilities measured at fair value or amortised costs are recognised. Moreover, all</td></tr><tr><td /><td>expenses incurred to achieve the earnings for the year are recognised in the income statement,</td></tr><tr><td /><td>including depreciations, amortisations, impairment losses and provisions as well as reversals due to</td></tr><tr><td /><td>changed accounting estimates of amounts that have previously been recognised in the income</td></tr><tr><td /><td>statement.</td></tr><tr><td /><td>Assets are recognised in the balance sheet when it is probable that future economic benefits attribut-</td></tr><tr><td /><td>able to the asset will flow to the Company, and the value of the asset can be measured reliably.</td></tr><tr><td /><td>Liabilities are recognised in the balance sheet when it is probable that future economic benefits will</td></tr><tr><td /><td>flow out of the Company, and the value of the liability can be measured reliably.</td></tr><tr><td /><td>Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured</td></tr><tr><td /><td>as described for each item below.</td></tr><tr><td /><td>Danish kroner is used as the measurement currency. All other currencies are regarded as foreign</td></tr><tr><td /><td>currencies.</td></tr></table> <table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td /><td>Translation policies</td></tr><tr><td /><td>Transactions in foreign currencies are translated at the exchange rate at the date of transaction.</td></tr><tr><td /><td>Gains and losses arising due to differences between the transaction date rate and the rates at the</td></tr><tr><td /><td>dates of payment are recognised in financial income and expenses in the income statement.</td></tr><tr><td /><td>Receivables, payables and other monetary items in foreign currencies that have not been settled at</td></tr><tr><td /><td>the balance sheet date are translated at the exchange rate at the balance sheet date. Any differences</td></tr><tr><td /><td>between the exchange rate at the balance sheet date and the transaction date rate are recognised in</td></tr><tr><td /><td>financial income and expenses in the income statement.</td></tr></table> <table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td /><td>Income Statement</td></tr></table> <table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td /><td>Other external expenses</td></tr><tr><td /><td>Other external expenses comprise of administration costs.</td></tr></table> <table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td /><td>Other operating income and expenses</td></tr><tr><td /><td>Other operating income and other operating expenses comprise of items of a secondary nature to the</td></tr><tr><td /><td>core activities of the enterprise, including gains and losses on the sale of intangible assets and</td></tr><tr><td /><td>property, plant and equipment.</td></tr></table> <table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td /><td>Financial income and expenses</td></tr><tr><td /><td>Financial income and expenses are recognised in the income statement at the amounts relating to the</td></tr><tr><td /><td>financial year. Financial income and expenses includes interest, bank charges and currency gains and</td></tr><tr><td /><td>losses.</td></tr></table> <table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td /><td>Tax on profit/loss for the year</td></tr><tr><td /><td>Tax for the year consists of current tax for the year and changes in deferred tax for the year. The tax</td></tr><tr><td /><td>attributable to the profit for the year is recognised in the income statement, whereas the tax</td></tr><tr><td /><td>attributable to equity transactions is recognised directly in equity.</td></tr><tr><td /><td>The Company is jointly taxed with Danish group enterprises. The tax effect of the joint taxation is</td></tr><tr><td /><td>allocated to Danish enterprises in proportion to their taxable incomes.</td></tr></table> <table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td /><td>Balance Sheet</td></tr></table> <table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td /><td>Receivables</td></tr><tr><td /><td>Receivables are measured in the balance sheet at the lower of amortised cost and net realisable value,</td></tr><tr><td /><td>which corresponds to nominal value less provisions for bad debts. Provisions for bad debts are deter-</td></tr><tr><td /><td>mined on the basis of objective evidence that a receivable or a group of receivables are impaired. As</td></tr><tr><td /><td>interpretation for impairment of financial receivables, the company has applied IAS 39.</td></tr></table> <table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td /><td>Cash</td></tr><tr><td /><td>Cash in the balance sheet comprise of cash at banks and in hand with an original maturity of</td></tr><tr><td /><td>three months or less.</td></tr></table> <table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td /><td>Deferred tax assets and liabilities</td></tr><tr><td /><td>Deferred income tax is measured using the balance sheet liability method in respect of temporary</td></tr><tr><td /><td>differences arising between the tax bases of assets and liabilities and their carrying amounts for</td></tr><tr><td /><td>financial reporting purposes on the basis of the intended use of the asset and settlement of the</td></tr><tr><td /><td>liability, respectively.</td></tr><tr><td /><td>Deferred tax assets, including the tax base of tax loss carry-forwards, are measured at the value at</td></tr><tr><td /><td>which the asset is expected to be realised, either by elimination in tax on future earnings or by set-off</td></tr><tr><td /><td>against deferred tax liabilities within the same legal tax entity.</td></tr><tr><td /><td>Deferred tax is measured on the basis of the tax rules and tax rates that will be effective under the</td></tr><tr><td /><td>legislation at the balance sheet date when the deferred tax is expected to crystallise as current tax.</td></tr><tr><td /><td>Any changes in deferred tax due to changes to tax rates are recognised in the income statement.</td></tr><tr><td /><td>Current tax receivables and liabilities</td></tr><tr><td /><td>Current tax liabilities and receivables are recognised in the balance sheet as the expected taxable</td></tr><tr><td /><td>income for the year adjusted for tax on taxable incomes for prior years and tax paid on account. Extra</td></tr><tr><td /><td>payments and repayment under the on-account taxation scheme are recognised in the income</td></tr><tr><td /><td>statement in financial income and expenses.</td></tr></table> <table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td /><td>Financial debts</td></tr><tr><td /><td>Financial liabilities are recognised on the raising of the loan at the proceeds received net of</td></tr><tr><td /><td>transaction costs incurred. Interest bearing debt is subsequently measured at amortised cost, using</td></tr><tr><td /><td>the effective interest rate method.</td></tr><tr><td /><td>Other debt is subsequently measured at amortised cost corresponding to the nominal unpaid debt.</td></tr></table> Årsrapport 34209936 Grant Thornton, Statsautoriseret Revisionspartnerselskab Stockholmgade 45 2100 København Ø xWizard version 1.1.1015.0, by EasyX Aps. www.easyx.eu 2019-01-01 2019-12-31 Revisionspåtegning Thomas Holst Laursen 198198 -198198 321272 15796 107278 -492989 600267 -3028693 600267 1127 1247722 1248849 29393609 30642458 30642458 4545875 25733357 30279232 363226 363226 363226 30642458 1907 3646209 3648116 29813870 33461986 33461986 4545875 28762050 33307925 154061 154061 154061 33461986 EY Godkendt Revisionspartnerselskab 30700228 Christian Schwenn Johansen State Authorised Public Accountant mne33234 Dirch Passers Allé 36 DK-2000 Frederiksberg